Objctive: In this study, we aimed to investigate the frequency and dosing of beta blocker use and the clinical conditions interfering withreaching the target doses in patients followed for heart failure with reduced ejection fraction.Material and Method: The study included 200 patients with a diagnosis of heart failure with reduced ejection fraction who were over18 years of age, had complete treatment and laboratory records, and had regularly been followed in our outpatient clinic for the previ‐ ous year.Results: In our study, 93% of patients were found to use beta blockers (62.5% metoprolol succinate, 26.5% carvedilol, 2.5% bisoprolol,and 1.5% nebivolol). The rate of using beta blockers at the target dose was only 9% (5% for metoprolol succinate and 15% for carvedilol).Only 55 (30%) of 186 patients using beta blockers reached 50% or more of the targeted dose. It was determined that beta blockers couldnot be commenced due to Raynaud’s phenomenon in 1 patient and active bronchospasm in 3 patients. The remaining 10 patients were found to have no interference with the use of beta blockers. There was no significant difference between patients using beta blockersat <50% and ≥50% of the target dose in terms of demographic data, heart rate, blood pressure, ejection fraction, New York Heart Association score, and beta blocker‐related side effects.Conclusion: In our study, although the vast majority of patients were using beta blockers, there was a very low number of patients usingbeta blockers at the target dose.